OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Woyach on 3-Year Follow-Up of Acalabrutinib/Obinutuzumab Combo in CLL

July 10th 2019

Jennifer Woyach, MD, discusses a 3-year follow-up looking at acalabrutinib with obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia.

Dr. Choueiri on Frontline Combination Therapies in mRCC

July 10th 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses the frontline combination therapies that are available for the treatment of patients with metastatic renal cell carcinoma (mRCC).

Dr. Raptis on DRd in Newly Diagnosed Multiple Myeloma

July 10th 2019

Anastasios Raptis, MD, a clinical assistant professor of medicine at the University of Pittsburgh School of Medicine Hillman Cancer Center, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) in the treatment of patients with newly diagnosed multiple myeloma.

Dr. Elhassadi on the Subtypes of MCL

July 10th 2019

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses the subtypes of mantle cell lymphoma (MCL).

Dr. Yu on Rationale for the KEYNOTE-365 Study in mCRPC

July 9th 2019

Evan Y. Yu, MD, discusses the rationale behind the KEYNOTE-365 trial, looking at pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Dr. Malhotra on Pembrolizumab During Concurrent Chemoradiation in NSCLC

July 9th 2019

Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.

Dr. Khushalani on Reasoning for the CA045-001 Trial

July 9th 2019

Nikhil Khushalani, MD, discusses the CA045-001 study, a phase III, randomized study that compared bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

Retesting for FLT3 Mutation Status in AML

July 9th 2019

Jordan Clark, the chief commercial officer at Diaceutics, discusses FLT3 retesting in a relapsed acute myeloid leukemia setting.

Dr. Sehgal on Managing CRS and Neurotoxicity From CAR T-Cell Therapy

July 9th 2019

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses ways to manage cytokine release syndrome (CRS) and neurotoxicity associated with CAR T-cell therapy.

Dr. Shadman on Fixed Durations of Treatment in CLL

July 9th 2019

Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington School of Medicine, and attending physician, Seattle Cancer Care Alliance, discusses fixed durations of treatment in chronic lymphocytic leukemia (CLL).

Dr. Meric-Bernstam on the Activity of Telaglenastat and Cabozantinib in mRCC

July 9th 2019

Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics, medical director of the Institute for Personalized Cancer Therapy, and a professor in the Divisions of Cancer Medicine and Surgery at The University of Texas MD Anderson Cancer Center, discusses the activity of the combination of telaglenastat (CB-839) and cabozantinib (Cabometyx) in heavily pretreated patients with metastatic renal cell carcinoma (mRCC).

Dr. Sullivan on Practice-Changing COMBI-d and COMBI-v Trials

July 5th 2019

Ryan J. Sullivan, MD, discusses the results of the COMBI-d and COMBI-v studies that led to changes in practice for patients with BRAF V600-mutant unresectable or metastatic melanoma.

Dr. Karmali on the Toxicity Profile of Ibrutinib Maintenance in MCL

July 4th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the toxicity profile of ibrutinib (Imbruvica) maintenance therapy after induction therapy in patients with mantle cell lymphoma (MCL).

Dr. Clarke on Available EGFR TKIs in Frontline Treatment of EGFR+ NSCLC

July 4th 2019

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses the available EGFR TKIs in the frontline setting for the treatment of patients with EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Cowan on Treatment Strategies in Transplant Eligible- and -Ineligible Myeloma

July 4th 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine and hematologist/oncologist at Seattle Cancer Care Alliance, discusses treatment strategies for patients with transplant-eligible and -ineligible multiple myeloma.

Dr. Sohal on Eligibility of Patients with Pancreatic Cancer for Clinical Trials

July 4th 2019

Davendra Sohal, MD, MPH, discusses the SWOG S1505 trial, which looks at initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.

Dr. Richardson Discusses the FDA Approval of Selinexor in Myeloma

July 3rd 2019

Paul Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the FDA approval of selinexor in multiple myeloma.

Dr. Kuzel on Immunotherapy as a Targeted Approach to Cancer

July 3rd 2019

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.

Dr. Polsky on Using ctDNA as a Biomarker for Melanoma

July 2nd 2019

David Polsky, MD, PhD, discusses using circulating tumor DNA kinetics as a biomarker to predict survival and monitor disease activity in patients with unresectable or metastatic melanoma.

Dr. Cristea on Investigational Maintenance Strategies in Ovarian Cancer

July 2nd 2019

Mihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.